Fulvio Lonardo, M.D.
Fulvio Lonardo, M.D.
Office Address3990 John R
Harper University Hospital, Department of Pathology
Detroit, MI 48201
Position TitleProfessor of Pathology
Dr. Lonardo’s specialty is in the anatomic pathologic of cancer. He has a sub-specialty expertise in cancers of lung and head and neck, for which serves as a reference pathologist and consultant.
Medical Education Responsibilities
- Lectures on Molecular and Morphological Basis of Cancer (5 hours), 2nd year Medical Students
- Lectures on Pathology of Neoplastic and non neoplastic lung diseases (2h), 2nd year Medical Students
- "Hands on" training of surgical pathology residents, daily
- Lectures on Lung pathology (4h), surgical pathology residents
- Lecture on Salivary gland pathology (1h), Head and Neck fellows and residents
- Lectures on Cellular basis of cancer, Ph D students (3h)
- Lectures on General Pathology of cancer, non Medical Professionals (3h)
Areas of InterestPulmonary Carcinogenesis, Molecular Pathogenesis of Lung Adenocarcinoma, Epidemiology of Lung Cancer, Role of Maspin in Lung Cancer
Together with S. Sheng, PhD. (Pathology), I have found that an exclusively nuclear expression, compared to a combined nuclear-cytoplasmic expression of the tumor suppressor protein maspin is common in adenocarcinoma, but not in squamous cell carcinoma of the lung. In addition, in limited stage adenocarcinoma nuclear maspin is linked with favorable clinical-pathological variables, including improved survival. These data, along with in vitro evidence, support the hypothesis that maspin's tumor suppressor ability depends on its nuclear localization. Ongoing research investigates the role of changes in maspin cellular localization in morphological progression in lung adenocarcinoma and its biochemical basis.
I am also involved in a prospective epidemiological study with Ann Schwartz PhD. (Internal Medicine) to address the hypothesis that gene polymporphisms in inflammatory genes may explain relative propensity to develop COPD vs. lung cancer in smokers.
In collaboration with G. Hillmann, PhD. (Radiology), I am studying a mice model of lung cancer to evaluate compounds with chemotherapeutic or radiation damage-protective activity.
Morphological-molecular relations in lung cancer. Molecular basis of maspin activity. Epidemiology of lung cancer.
1990-1994: University of Rochester Medical Center, Rochester, NY, USA, in Anatomic Pathology
1. Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI, and Sheng S, 2006, Maspin nuclear localization is linked to favorablemorphological features in pulmonary adenocarcinoma, Lung Cancer, 51: 31-9.
2. Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, Skafar DF, and Lonardo F, 2007, Reproductive factors, hormone
use, estrogen receptor expression and risk in non small cell lung cancer in women, J Clin Oncol, 36: 5785-92.
3. Frey AB, Wali A. Pass H, and Lonardo F, 2007, Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but
not in malignant pleural mesothelioma, HistoPathol, 50: 720-6.
4. Van Dyke AL, Cote ML, Prysak G, Claeys B, Wenzlaff A, Murphy V, Lonardo F, and Schwartz A, 2008, COX 2/EGFR expression and
Survival among women with adenocarcinoma of the lung, Carcinogenesis, 2008, 29: 1781-7.
5. Frey A, Soubani AO, Adam, AK, Sheng, S, Pass, HI, and Lonardo F, 2009, Nuclear, compared to combined nuclear and cytoplasmic
expression of maspin is linked in lung adenocarcinoma to reduced VEGFA Levels and in Stage I, Improved Survival, HistoPathol, 54: 590-
6. Lonardo, F., et al.: The natural tumor suppressor protein maspin and potential application in non small cell lung cancer. Current
pharmaceutical design. 2010;16(16): 1877-81.
7. Cote ML, Haddad R, Edwards E, Atikukke A, Gadgeel S, Soubani AO, Lonardo F, Bepler G, Schwartz AG, Ethier S: Frequency and type
of EGFR mutations in African Americans with NSCLC. J Thorac Oncol 2011;6:627-630
8. Li X, Kaplun A, Lonardo F, Heath E, Sarkar F, Irish J, Sakr W, Sheng S.: HDAc1 inhibition by maspin abrogates epigenetic silencing of
GST Pi in prostate carcinoma cells. Mol Can Res 2011; Jun 9(6):733-45.